UiPath saw its IBD SmartSelect Composite Rating rise to 97 Wednesday, up from 90 the day before.
The new rating shows the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria.
UiPath is currently forming a stage 1 cup pattern, with an 18.12 buy point. See if the stock can break out in heavy trade at least 40% above average.
See How IBD Helps You Make More Money In Stocks
The stock sports an 81 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 81% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company reported 0% EPS growth. Revenue growth increased 18%, up from 7% in the prior report. That marks one quarter of rising revenue growth.
UiPath holds the No. 13 rank among its peers in the Computer Software-Enterprise industry group. Salesforce, Dynatrace and JFrog are among the top 5 highly-rated stocks within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
